464.71

1.92% -9.08

Madrigal Pharmaceuticals Inc (MDGL)

개요 뉴스 가격 이력 옵션 체인 Financials MDGL 왜 하락? 토론 예측 주식 분할

전일 마감가:

$473.79

열려 있는:

$474.31

하루 거래량:

245.70K

Relative Volume:

0.76

시가총액:

$10.55B

수익:

순이익/손실:

$-518.67M

주가수익비율:

-18.50

EPS:

-25.12

순현금흐름:

$-438.32M

1주 성능:

-2.70%

1개월 성능:

-5.91%

6개월 성능:

+24.43%

1년 성능:

+32.13%

1일 변동 폭

$458.07

$482.99

1주일 범위

$458.07

$499.55

52주 변동 폭

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

명칭

Madrigal Pharmaceuticals Inc

부문

Healthcare (1111)

산업

Biotechnology (622)

전화

404-380-9263

주소

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

직원

528

트위터

@MadrigalPharma

다음 수익 날짜

2024-10-31

최신 SEC 제출 서류

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
MDGL Madrigal Pharmaceuticals Inc	464.71	10.76B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-01-28	개시	Barclays	Overweight
2026-01-06	다운그레이드	Wolfe Research	Outperform → Peer Perform
2025-11-05	업그레이드	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	업그레이드	BofA Securities	Underperform → Neutral
2025-10-15	개시	Truist	Buy
2025-09-04	재개	H.C. Wainwright	Buy
2025-02-28	업그레이드	B. Riley Securities	Neutral → Buy
2025-02-27	재확인	H.C. Wainwright	Buy
2024-06-28	개시	Cantor Fitzgerald	Neutral
2024-06-11	개시	Wolfe Research	Outperform
2024-04-22	개시	BofA Securities	Underperform
2024-03-15	업그레이드	B. Riley Securities	Sell → Neutral
2024-03-06	개시	Citigroup	Buy
2024-02-26	다운그레이드	B. Riley Securities	Neutral → Sell
2022-12-20	재확인	Oppenheimer	Outperform
2022-12-19	재확인	H.C. Wainwright	Buy
2022-12-19	재확인	Piper Sandler	Overweight
2022-12-19	업그레이드	Raymond James	Underperform → Mkt Perform
2022-07-08	다운그레이드	B. Riley Securities	Buy → Neutral
2021-10-07	개시	Jefferies	Buy
2021-08-06	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-05-20	재개	Goldman	Buy
2020-11-24	재개	Evercore ISI	Outperform
2020-11-06	재확인	H.C. Wainwright	Buy
2020-07-31	개시	Piper Sandler	Overweight
2020-06-05	개시	BMO Capital Markets	Market Perform
2020-05-05	개시	Chardan Capital Markets	Buy
2020-01-30	개시	Canaccord Genuity	Buy
2020-01-09	업그레이드	UBS	Neutral → Buy
2019-11-07	재확인	H.C. Wainwright	Buy
2019-06-25	개시	Stifel	Hold
2019-06-10	업그레이드	B. Riley FBR	Neutral → Buy
2019-02-28	재확인	H.C. Wainwright	Buy
2019-02-22	개시	SVB Leerink	Outperform
2019-01-23	개시	UBS	Neutral
2018-12-14	개시	Wolfe Research	Outperform
2018-12-12	개시	B. Riley FBR	Neutral
2018-11-19	다운그레이드	Raymond James	Mkt Perform → Underperform
2018-11-16	업그레이드	Evercore ISI	In-line → Outperform
2018-09-04	개시	Citigroup	Buy
2018-08-06	다운그레이드	Goldman	Buy → Neutral
2018-06-28	개시	Raymond James	Mkt Perform

모두보기

Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스

02:41 AM

Why Madrigal Pharmaceuticals Inc. stock is seen as undervaluedWeekly Investment Report & Scalable Portfolio Growth Methods - mfd.ru

02:41 AM

Feb 13, 2026

Madrigal Pharmaceuticals is Now Oversold (MDGL) - Nasdaq

Feb 13, 2026

Feb 12, 2026

What are Madrigal Pharmaceuticals Inc.’s recent SEC filings showingMarket Risk Summary & Daily Stock Trend Reports - mfd.ru

Feb 12, 2026

MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz

Feb 12, 2026

Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Feb 12, 2026

Madrigal expands MASH pipeline with siRNA therapies in $4.4 B deal - BioSpectrum Asia

Feb 11, 2026

Suzhou Ribo Life Science Signs Global siRNA Licensing Deal With Madrigal Pharma; Shares Rise 7% - marketscreener.com

Feb 11, 2026

What are analysts’ price targets for Madrigal Pharmaceuticals Inc.Price Action & Low Risk Growth Stock Ideas - mfd.ru

Feb 11, 2026

Is Madrigal Pharmaceuticals Inc. in a long term uptrendJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru

Feb 11, 2026

Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal - Citeline News & Insights

Feb 11, 2026

What is Madrigal Pharmaceuticals Inc. s revenue forecastJuly 2025 Update & Accurate Trade Setup Notifications - mfd.ru

Feb 11, 2026

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - Finviz

Feb 11, 2026

Madrigal builds in MASH with $4.4bn+ Ribo alliance - pharmaphorum

Feb 11, 2026

Madrigal Pharmaceuticals (MDGL) Secures $4.46B Licensing Deal wi - GuruFocus

Feb 11, 2026

Madrigal licenses six Ribo siRNA programs - bioworld.com

Feb 11, 2026

Madrigal inks licensing deal for MASH drugs (MDGL:NASDAQ) - Seeking Alpha

Feb 11, 2026

Madrigal expands its MASH pipeline with exclusive global licensing agreement for six preclinical siRNA programs - marketscreener.com

Feb 11, 2026

Madrigal, China's Suzhou Ribo sign license deal for liver-disease programs - marketscreener.com

Feb 11, 2026

Madrigal turns to RNAi drugs from China to bolster MASH pipeline - Yahoo Finance

Feb 11, 2026

Madrigal, Suzhou Ribo in license deal for liver-disease programs - marketscreener.com

Feb 11, 2026

Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits

Feb 11, 2026

Madrigal Pharmaceuticals (MDGL) Secures Global License for siRNA Programs - GuruFocus

Feb 11, 2026

Madrigal Pharmaceuticals, Inc. announced an exclusive global licensing agreement to introduce six preclinical-stage siRNA (small interfering RNA) programs, aiming to significantly expand its research and development pipeline for metabolic dysfunction-asso - Bitget

Feb 11, 2026

Madrigal Pharmaceuticals Expands MASH Pipeline with Exclusive License for siRNA Programs - Quiver Quantitative

Feb 11, 2026

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewswire

Feb 11, 2026